Related Experiment Videos
Cefotetan disodium-induced hemolytic anemia.
B K Wagner1, A H Heaton, J R Flink
1Pharmacy Service, United Hospital, St. Paul, MN 55102.
The Annals of Pharmacotherapy
|February 1, 1992
Summary
Cefotetan disodium can cause severe hemolytic anemia, even after repeated use. This case highlights the need for careful monitoring of patients receiving this antibiotic, especially during multiple treatment courses.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Cefotetan disodium is a cephalosporin antibiotic used for surgical prophylaxis.
- Drug-induced hemolytic anemia is a known adverse effect of some medications.
- While rare, cephalosporin-induced hemolysis necessitates continued vigilance.
Observation:
- A 46-year-old woman experienced fulminant hemolytic anemia after a second exposure to intravenous cefotetan disodium.
- The patient developed severe complications including respiratory and acute renal failure.
- Despite plasmapheresis, the patient's outcome was fatal.
Findings:
- This case represents the first reported instance of fulminant hemolytic anemia linked to intravenous cefotetan disodium.
- Positive Coomb's tests are infrequently associated with cefotetan, making this severe reaction noteworthy.
- The patient's severe presentation underscores the potential for cefotetan to induce significant hemolysis.
Implications:
- Cefotetan disodium should be recognized as a potential cause of drug-induced hemolytic anemia.
- Clinicians should consider monitoring for hemolysis in patients undergoing multiple courses of cefotetan therapy.
- Awareness of this adverse effect is crucial for patient safety and appropriate clinical management.